Consistent with previous studies [38, 39], TET2 and DNMT3A mutations were observed in non‐tumor cells including myeloid or B‐cells, suggesting early founding mutation in a progenitor cell in a subset of cases, but other mutations like IDH2, RHOA, and CD28 appeared to be tumor‐specific. This evidence concerns the gene TET2 and neoplasm.